Brief: Valbiotis Signs Global Strategic Partnership With Nestlé Health Science

Valbiotis SA

05/02/2020 17:07

Feb 5 (Reuters) - Valbiotis SA  ALVAL.PA :
    * VALBIOTIS ANNOUNCES SIGNATURE OF GLOBAL STRATEGIC
PARTNERSHIP
WITH NESTLÉ HEALTH SCIENCE FOR DEVELOPMENT AND COMMERCIALIZATION
OF TOTUM-63
    * UNDER THE TERMS OF THE AGREEMENT, VALBIOTIS GRANTS NESTLÉ
HEALTH
SCIENCE EXCLUSIVE AND WORLDWIDE COMMERCIAL RIGHTS TO USE THE
PATENTED COMPOSITION TOTUM-63 IN THE PREDIABETES AND TYPE 2
DIABETES MARKET
    * TOTUM-63 MAY BE MARKETED PRIOR TO OBTAINING THE HEALTH
CLAIMS
    * AGREEMENT INCLUDES AN INITIAL PAYMENT OF 5 MILLION SWISS
FRANCS,
MILESTONE PAYMENTS OF UP TO 66 MILLION SWISS FRANCS AND
PROGRESSIVE ROYALTIES ON NET SALES
    * RESUMPTION OF TRADING OF VALBIOTIS SHARES ON EURONEXT
GROWTH
WILL TAKE PLACE ON FEBRUARY 6, 2020 AT 9:00 AM
    * THE AGREEMENT ALSO INCLUDES THE SUPPLY OF NESTLÉ HEALTH
SCIENCE
WITH TOTUM-63 BY VALBIOTIS, REPRESENTING AN ADDITIONAL SOURCE OF
REVENUE

Source text : https://bit.ly/2UrFJat
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587785110;))